Neoadjuvant immunotherapy enhances radiosensitivity through natural killer cell activation

Area of Science:

• Immunology
• Oncology
• Radiotherapy

Background:

• The tumor microenvironment's role in cancer treatment response is crucial.
• Natural killer (NK) cells are key immune components within the tumor microenvironment.
• Investigating immunotherapies that enhance radiosensitivity is a significant area of cancer research.

Purpose of the Study:

• To determine if NK cells contribute to radiosensitization.
• To evaluate the radiosensitizing effect of combined CpG and Herceptin (CpG/Herceptin) immunotherapy.
• To assess the optimal timing of immunotherapy administration relative to radiotherapy.

Main Methods:

• In vitro studies involved co-culturing a murine colon cancer cell line (CT26HER2/neu) with splenocytes, CpG, and Herceptin before irradiation.
• In vivo studies used BALB/c mice bearing CT26HER2/neu tumors, comparing CpG/Herceptin administration before versus after radiotherapy.
• NK cell depletion was performed to ascertain their role in the observed radiosensitization.

Main Results:

• Tumor cells co-cultured with CpG-pretreated splenocytes and Herceptin showed increased radiosensitivity in vitro.
• CpG/Herceptin administered before radiotherapy significantly inhibited tumor growth compared to post-radiotherapy administration in vivo.
• The radiosensitization effect was abolished upon NK cell depletion, highlighting their essential role.
• Surviving mice developed resistance to tumor re-challenge, indicating an induced immune response.

Conclusions:

• NK cells play a critical role in the radiosensitization effect induced by CpG/Herceptin immunotherapy.
• Neoadjuvant immunotherapy with CpG/Herceptin shows promise for improving radiotherapy outcomes in HER2/neu-expressing tumors.
• This approach may enhance anti-tumor immunity, leading to long-term protection.